Quirce Santiago, Heffler Enrico, Nenasheva Natalia, Demoly Pascal, Menzies-Gow Andrew, Moreira-Jorge Ana, Nissen Francis, Hanania Nicola A
Department of Allergy, La Paz University Hospital, IdiPAZ and Universidad Autónoma de Madrid, Madrid, Spain.
Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, MI, Italy.
J Asthma Allergy. 2020 Dec 31;13:743-752. doi: 10.2147/JAA.S282205. eCollection 2020.
The Global Initiative for Asthma (GINA) 2020 defines late-onset asthma (LOA) as one of the clinical phenotypes of asthma wherein patients, particularly women, present with asthma for the first time in adult life, tend to be non-allergic and often require higher doses of inhaled corticosteroids (ICS) or are relatively refractory to corticosteroid treatment. In this review, we examine the published literature improve the understanding of the following aspects of LOA: 1) the age cut-off for its diagnosis; 2) its distinct clinical phenotypes, characteristics and risk factors; and 3) its association with allergic comorbidities and conditions. Overall, our review reveals that clinicians and researchers have used multiple age cut-offs to define LOA, with cut-off ages ranging from >12 years to ≥65 years. LOA has also been classified into several distinct phenotypes, some of which drastically differ in their clinical characteristics, course and prognosis. Although LOA has traditionally been considered non-allergic in nature, our review indicates that it is commonly associated with allergic features and comorbidities. Our findings suggest that there is an urgent need for the development of more clear clinical practice guidelines that can provide more clarity on the definition and other aspects of LOA. In addition, the association of LOA and allergy needs to be re-examined to frame a more optimal treatment strategy for patients with LOA.
全球哮喘防治创议(GINA)2020将迟发性哮喘(LOA)定义为哮喘的临床表型之一,在这类患者中,尤其是女性,在成年期首次出现哮喘,往往是非过敏性的,且通常需要更高剂量的吸入性糖皮质激素(ICS),或者对糖皮质激素治疗相对难治。在本综述中,我们研究已发表的文献,以增进对LOA以下方面的理解:1)其诊断的年龄界限;2)其独特的临床表型、特征和危险因素;3)其与过敏性合并症和疾病的关联。总体而言,我们的综述表明,临床医生和研究人员使用了多个年龄界限来定义LOA,年龄界限范围从>12岁到≥65岁。LOA也已被分为几种不同的表型,其中一些在临床特征、病程和预后方面有很大差异。尽管传统上认为LOA本质上是非过敏性的,但我们的综述表明,它通常与过敏特征和合并症相关。我们的研究结果表明,迫切需要制定更明确的临床实践指南,以便能更清晰地界定LOA的定义及其他方面。此外,需要重新审视LOA与过敏的关联,以便为LOA患者制定更优化的治疗策略。